Acetyl-TP53 (K320) Antibody

What is Acetyl-TP53 (K320) Antibody and what does it specifically detect?

Acetyl-TP53 (K320) Antibody is a polyclonal antibody produced in rabbits that specifically recognizes the acetylated form of tumor protein p53 at lysine 320. This antibody is designed to detect the post-translational modification of p53 that occurs at a specific lysine residue (K320), which plays a crucial role in regulating p53's function as a transcription factor. The antibody is generated using a synthesized acetyl-peptide derived from human p53 around the acetylation site of K320 as the immunogen . This specificity allows researchers to distinguish this particular acetylation state from other post-translational modifications of p53, enabling detailed studies of p53 regulation and function.

How does acetylation at K320 affect p53 function compared to other acetylation sites?

Acetylation at K320 has distinct functional consequences compared to acetylation at other sites, particularly K373. Research shows that K320 acetylation predominantly promotes cell survival pathways, while acetylation at sites around position 373 activates apoptotic pathways . This functional distinction has significant implications for cellular fate decisions following DNA damage.

Specifically, experiments with acetylation-mimicking mutants (p53Q320 and p53Q373) have demonstrated that:

• Cells expressing p53Q320 (mimicking acetylation at K320) show enhanced activation of the G1 checkpoint and protection from cell death when treated with DNA-damaging agents .

• Cells expressing p53Q373 (mimicking acetylation at K373) demonstrate increased sensitivity to apoptosis following DNA damage .

• When both sites are modified (p53DM), the protective effect of K320 acetylation appears dominant, suggesting a hierarchical relationship between these modifications .

These differences in cellular outcomes are reflected in distinct gene expression profiles, with K320 acetylation promoting expression of cell cycle arrest genes while downregulating proapoptotic genes, and K373 acetylation showing the opposite pattern .

What are the recommended applications for Acetyl-TP53 (K320) Antibody?

The Acetyl-TP53 (K320) Antibody has been validated for specific research applications:

• Western Blot (WB): Recommended dilution range of 1:500-1:2000 .

• ELISA: Recommended dilution of 1:20000 .

These applications allow researchers to detect and quantify K320-acetylated p53 in various experimental contexts, including after treatment with DNA-damaging agents or other cellular stressors. The antibody has not been validated for immunohistochemistry (IHC), immunofluorescence (IF), or immunoprecipitation (IP) based on the provided information, although these applications might be feasible with proper optimization.

How should I design experiments to study differential effects of K320 versus K373 acetylation?

Based on research findings, designing experiments to distinguish between the effects of K320 and K373 acetylation requires careful consideration of several factors:

• Selection of DNA-damaging agents: Different DNA-damaging agents trigger distinct acetylation patterns. For instance, studies show that while adozelesin (a monofunctional DNA minor groove alkylating agent) and bizelesin (a CPI dimer capable of forming double-stranded DNA cross-links) both induce p53 acetylation, they do so with different kinetics and at different sites . Etoposide (a topoisomerase inhibitor) also produces distinct acetylation patterns .

• Dose and time-dependent considerations: Research indicates that:

  • K320 acetylation occurs rapidly after DNA damage but is relatively less sensitive to increases in damage dose .

  • K373 acetylation shows dose-dependent enrichment, with higher levels of DNA damage producing greater K373 acetylation .

• Experimental approach options:

  • Use acetylation-mimicking mutants (e.g., p53Q320 and p53Q373) to isolate effects of specific acetylation sites .

  • Apply site-specific acetylation antibodies to monitor endogenous modifications.

  • Employ deacetylase inhibitors to modulate acetylation levels.

  • Use cells expressing wild-type versus mutant p53 (K320R or K373R) to study loss of specific acetylation sites.

A comprehensive experimental design should include multiple time points following DNA damage and varying doses of damaging agents to capture the dynamic nature of these modifications.

What controls should I include when using Acetyl-TP53 (K320) Antibody?

When working with the Acetyl-TP53 (K320) Antibody, several crucial controls should be included:

• Positive control: Lysates from cells treated with agents known to induce K320 acetylation, such as adozelesin or etoposide at established time points post-treatment .

• Negative controls:

  • p53-null cells (to confirm antibody specificity)

  • Cells expressing p53 with K320R mutation (prevents acetylation at this site)

  • Non-specific IgG control for immunoprecipitation experiments

• Acetylation verification controls:

  • Treatment with histone deacetylase inhibitors to increase acetylation levels

  • Parallel detection with a pan-p53 antibody to assess total p53 levels

  • Comparison with other site-specific acetylation antibodies (e.g., K373) to distinguish acetylation patterns

• Peptide competition assay: Pre-incubating the antibody with the acetylated peptide immunogen should abolish specific signal, confirming antibody specificity.

Including these controls will ensure reliable interpretation of results and help troubleshoot any technical issues.

What is the optimal Western blot protocol for detecting acetylated p53 at K320?

For optimal detection of acetylated p53 at K320 using Western blot, the following protocol is recommended:

• Sample preparation:

  • Harvest cells at appropriate time points after treatment

  • Lyse cells in buffer containing deacetylase inhibitors (e.g., trichostatin A, nicotinamide)

  • Include protease inhibitors to prevent degradation

  • Clear lysates by centrifugation

• Gel electrophoresis and transfer:

  • Resolve 20-50 μg protein on 10% SDS-PAGE

  • Transfer to PVDF or nitrocellulose membrane

• Antibody incubation:

  • Block membrane with 5% non-fat milk or BSA in TBST

  • Incubate with Acetyl-TP53 (K320) Antibody at 1:500-1:2000 dilution overnight at 4°C

  • Wash thoroughly with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody

  • Wash thoroughly with TBST

• Detection:

  • Develop using enhanced chemiluminescence (ECL)

  • Expose to X-ray film or image using digital system

• Analysis:

  • Strip and reprobe with total p53 antibody to normalize acetylation levels

  • Quantify band intensity using appropriate software

This protocol should be optimized for specific cell types and experimental conditions.

How can I optimize sample preparation to preserve p53 acetylation status?

Preserving p53 acetylation status during sample preparation is critical for accurate results. Follow these recommendations:

• Rapid processing: Minimize the time between cell harvest and protein denaturation to prevent deacetylation by endogenous enzymes.

• Deacetylase inhibitors: Include multiple deacetylase inhibitors in lysis buffers:

  • HDAC inhibitors (e.g., trichostatin A at 1 μM)

  • SIRT1 inhibitors (e.g., nicotinamide at 5-10 mM)

  • This is particularly important as research shows that HDAC1, mSin3, and SIRT1 interact with acetylated p53 .

• Lysis conditions:

  • Use denaturing conditions when possible

  • Include phosphatase inhibitors (as phosphorylation and acetylation can influence each other)

  • Maintain samples at 4°C during processing

• Avoid freeze-thaw cycles: Process samples immediately or aliquot and freeze at -80°C, avoiding repeated freeze-thaw cycles .

• Consider crosslinking: For certain applications, mild crosslinking before lysis may help preserve protein complexes and modifications.

These precautions are essential as acetylation is a labile modification that can be rapidly reversed by cellular deacetylases that remain active in many lysis conditions.

How does K320 acetylation influence p53's interaction with transcriptional cofactors?

Research demonstrates that acetylation at different sites on p53 significantly alters its interaction with transcriptional cofactors:

• Histone acetyltransferase interactions:

  • p53 acetylated at K320 (or the mimetic p53Q320) shows enhanced interaction with PCAF (p300/CBP-associated factor) .

  • p53 acetylated at K373 (or the mimetic p53Q373) demonstrates stronger binding to p300 .

• Deacetylase/corepressor recruitment:

  • K373 acetylation significantly increases p53's association with HDAC1 and mSin3 corepressor complexes .

  • This enhanced recruitment of deacetylase/corepressor complexes may explain the stronger transcriptional repression observed with p53Q373 compared to p53Q320 .

• Temporal dynamics:

  • The interaction between K373-acetylated p53 and deacetylases like HDAC1 and SIRT1 is stable and detectable for at least 12 hours after DNA damage .

  • This suggests a feedback mechanism where specific acetylation states recruit the enzymes that will eventually reverse them.

These differential interactions with transcriptional cofactors help explain how site-specific acetylation patterns translate into distinct gene expression profiles and cellular outcomes.

What gene expression patterns are associated with p53 K320 acetylation versus K373 acetylation?

Microarray analyses have revealed distinct gene expression patterns associated with different p53 acetylation states:

This differential gene regulation provides a molecular explanation for the observation that K320 acetylation promotes cell survival while K373 acetylation enhances apoptotic responses.

Why might I see weak or non-specific signals when using Acetyl-TP53 (K320) Antibody?

Several factors can contribute to weak or non-specific signals when using the Acetyl-TP53 (K320) Antibody:

• Low acetylation levels:

  • Insufficient DNA damage or stress to induce K320 acetylation

  • Incorrect timing of sample collection (acetylation is dynamic)

  • Active deacetylases in sample preparation

• Technical factors affecting antibody performance:

  • Improper dilution (recommended range is 1:500-1:2000 for WB)

  • Insufficient blocking or inadequate washing

  • Secondary antibody issues (concentration, specificity)

  • Buffer composition incompatibility

• Sample preparation issues:

  • Protein degradation during sample preparation

  • Insufficient deacetylase inhibitors in lysis buffer

  • Protein denaturation affecting epitope recognition

• Detection sensitivity limitations:

  • ECL reagent potency

  • Exposure time issues

  • Membrane choice (PVDF typically provides higher sensitivity than nitrocellulose)

To address these issues, consider optimizing your experimental conditions, including treatment protocols to maximize K320 acetylation, improving sample preparation with appropriate inhibitors, and adjusting antibody dilutions and incubation conditions.

How can I distinguish between K320 acetylation and other post-translational modifications of p53?

Distinguishing between K320 acetylation and other post-translational modifications requires careful experimental design:

• Use of multiple site-specific antibodies:

  • Compare signals from Acetyl-TP53 (K320) Antibody with antibodies against other modified residues

  • This approach can reveal distinct patterns of modifications under different conditions

• Mass spectrometry analysis:

  • For definitive identification of modifications, immunoprecipitate p53 and analyze by mass spectrometry

  • This can identify all modifications present on p53 simultaneously

• Mutational analysis:

  • Compare wild-type p53 with K320R mutant (prevents acetylation)

  • K320Q mutant (mimics constitutive acetylation)

  • Other site-specific mutants (K373R, etc.)

• Enzyme inhibitor studies:

  • Use specific deacetylase inhibitors (HDAC vs. SIRT inhibitors)

  • Compare with effects of phosphatase inhibitors

• Sequential immunoprecipitation:

  • First IP with one modification-specific antibody, then probe the immunoprecipitate with antibodies against other modifications

  • This reveals which modifications co-occur on the same p53 molecules

Understanding the interplay between various post-translational modifications is important, as research shows that acetylation at K320 can influence phosphorylation of serines in the NH2-terminal region of p53, demonstrating functional interference between these modifications .

How might K320 acetylation be therapeutically relevant in cancer research?

The distinct cellular outcomes associated with different p53 acetylation patterns suggest several potential therapeutic applications:

• Targeted modulation of acetylation patterns:

  • Developing compounds that specifically enhance K373 acetylation could potentially sensitize cancer cells to chemotherapy by promoting apoptosis .

  • Conversely, agents promoting K320 acetylation might be useful for protecting normal cells from chemotherapy-induced damage .

• Personalized medicine applications:

  • Analyzing p53 acetylation patterns in patient tumors could predict response to DNA-damaging therapies

  • This could guide selection of appropriate treatment regimens based on likely cellular responses

• Development of acetylation status biomarkers:

  • Using antibodies like Acetyl-TP53 (K320) in diagnostic applications to predict tumor behavior

  • Monitoring acetylation patterns during treatment to assess response

• Targeting acetylation-dependent protein interactions:

  • Developing compounds that disrupt or enhance specific interactions between acetylated p53 and its binding partners

  • This could potentially redirect cellular responses to DNA damage

Given that the balance between K320 and K373 acetylation appears to function as a molecular switch between cell survival and apoptosis, therapeutic approaches that tip this balance could have significant implications for cancer treatment strategies.

What methods can be used to study the temporal dynamics of p53 K320 acetylation?

Understanding the temporal dynamics of p53 K320 acetylation requires specialized experimental approaches:

• Time-course experiments:

  • Treat cells with DNA-damaging agents and collect samples at multiple time points

  • Western blot analysis using Acetyl-TP53 (K320) Antibody (1:500-1:2000 dilution)

  • Normalize to total p53 levels to account for p53 stabilization after damage

• Live-cell imaging techniques:

  • Generate cells expressing fluorescent-tagged p53

  • Use fluorescently labeled acetyl-lysine binding domains

  • Perform fluorescence resonance energy transfer (FRET) to monitor acetylation in real time

• ChIP-seq analysis:

  • Chromatin immunoprecipitation with Acetyl-TP53 (K320) Antibody followed by sequencing

  • This can reveal the genomic binding sites of K320-acetylated p53 at different time points after DNA damage

  • Compare with ChIP-seq using antibodies against other modified forms of p53

• Pulse-chase approaches:

  • Use inducible expression systems to control when p53 is expressed

  • Monitor acetylation status over time using Acetyl-TP53 (K320) Antibody

  • This approach can distinguish between newly synthesized and pre-existing p53

Research has shown that different DNA-damaging agents induce distinct kinetics of K320 versus K373 acetylation, highlighting the importance of temporal resolution in these studies .